Refine/Revise Search
Asking Price: Not Disclosed

Outstanding OC Independent Commercial Agency

Irvine, CA
Orange County

This 16-year-old commercial-focused agency was started by an individual who brought in a partner in 2012 to manage and develop the Property and Casualty division. This division grew from $600,000 in Premium to $6,500,000, more than 1,500 policies, and nearly $875,000 in annual commissions and fees.Contractors are the Agency’s Commercial Market niche, representing 65% of their Commercial policies. These include General Liability, Excess Liability, Commercial Auto, and Worker’s Comp.Personal Lines account for 35% of the policies.Several top carriers are offered via the Smart Choice Cluster which accounts for $1.8M of total premium. The ability to transfer the cluster relationship to a Buyer is pre-approved. This means potential Buyers do not require existing appointments with Mercury, Travelers, Liberty Mutual, Guard, and others. The contract fee is grandfathered in which is subtracted from monthly commissions. Income reports reflect this expense. There is nothing extra to be paid.The Seller currently manages all aspects of the Business including administrative roles (payroll, invoicing, audits, agency staff hiring, training, and management) and all accounting and financial tasks including customer payments, carrier payments, QuickBooks, etc.The Seller personally manages $4M in commercial premiums with the help of one assistant account manager and one part-time commercial account manager. She also assists the Personal Lines Account Manager as needed to place business, and set up new appointments. Those accounts bring in $2M in premiums.NDA is required to secure the comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.

Cash Flow $466,000
Revenue $875,000
$ Owner Financing Available

Asking Price: $30,000,000

Direct Lending & Real Estate Investments Services

Not Disclosed, CA
Not disclosed

Transworld Business Advisors of Orange presents:*** The Business is Currently Under Contract ***In business for 30 years, this 100% service-oriented company has been highly profitable and provides direct lending services and real estate investments.The business enjoys a stellar reputation and brand awareness in the industry, serving thousands of clients and investors over the decades.The business has been on a strong upward curve, with an average year over year revenue growth of over 35% since 2020. It has well-developed systems and processes in place to allow for future growth and expansion.Other investment highlights include:- A multi-source revenue business including loan origination, servicing, investments and trustee fees, thus controlling and benefiting from all aspects of the life cycle of the loan.- Long-term relationships between the business and, brokers and investors.- Great employees with experienced leaders in each department.- Serving clients in eight states (starting in 2020) with expected expansion onto additional states within the next two years.- On average, the company closes 60 to 100 loans each month, with most months exceeding 75.- As one of the oldest private money lenders in California, the pipeline of the business is largely generated by broker referrals.*** $5,000,000 in cash or trust deeds included in the sale. ***The owner is retiring after 20 years in the business and will help the new owners with transition.Agent: Nassim Bayat DRE# 01958611

Cash Flow $5,680,586
Revenue $13,283,263

Asking Price: $20,000,000

Patented Universal Tumor-Targeting Drug Delivery

Irvine, CA
Orange County

Patented Universal Tumor-Targeting Drug Delivery Platform Co.This pharmaceutical company has developed and patented a universal tumor-targeting drug-delivery platform that can improve the safety and efficacy of many existing chemo treatments, with the ability to target numerous different types of cancer. The technology encapsulates existing FDA-approved drugs inside lipid nanoparticles (liposomes or emulsions) coated with patented human-sourced antinuclear antibodies (ANA). The lipid nanoparticle provides long-term storage stability of the drug and controlled release of the drug over time at body-temperature, and is expected to improve the safety and efficacy profile of the drug, including passive accumulation at the tumor while not harming normal tissues. The Company’s ANA, sourced from lupus patients, binds to nuclear material present in abundance in areas of necrosis (dead / ruptured cells) present in and around all solid tumors, thus anchoring the drug-filled nanoparticles at the tumor where the nanoparticle is designed to slowly release the drug directly on the tumor for more effect. As the Company’s ANA is not tumor-marker specific, but rather targets necrosis present in solid tumors, the technology is designed to 'universally' target many different types of cancer including breast cancer, lung, ovarian, colon, prostate, etc., as well as rare childhood cancers.The Company completed a successful proof-of-concept study at Children's Hospital using Ewing's Sarcoma transplanted in immunodeficient mice. Treatment with the Company's forumlation significantly inhibited tumor growth and extended survival times compared to control mice receiving no treatment or treatment with plain liposomal doxorubicin.The Company has been granted Orphan Drug Designation by the FDA on 2 of the lead drug formulations, providing FDA fee waivers, priority review, and 7-years exclusivity upon market approval. The orphan pathway also enables the potential for New Drug Approval after successful completion of Phase 2 studies, with Phase III data collected while in the market, thus significantly lowering the time and cost to market approval. This same drug inside the Company's tumor targeting delivery system will likely have potential to treat other pediatric cancers, and/or cancers in larger adult populations.As the Company’s platform and ANA has the potential to improve the safety and efficacy of many existing FDA approved drugs or even compounds in development, the Company anticipates the potential for multiple licensing agreements with multiple pharmaceutical companies seeking to improve their existing portfolio and extend patient life as they advance into clinical stage. And as it may be possible to file for New Drug Approval following successful Phase II studies, the Company anticipates licensing potential at early clinical stage. Multiple exit opportunities exist with high impact & high ROI.The Company is seeking a supportive capital partner to maintain momentum up to $20M. Funding will be used to advance the lead drug through formal Investigational New Drug enabling studies towards New Drug Approval; estimating $3-5 Million now to advance into clinical studies. Preclinical / animal studies estimate ($3 - 5 Million and 12-18 months); followed by potential combined Phase I-II clinical study in a rare cancer (approximately 2-3 years and $10M) to potential New Drug Approval, plus additional capital to advance additional drugs in the pipeline simultaneously, thus adding tremendous value to the Company’s valuation. Valuations of pharma companies often exceed $100 Million valuation at Phase I (approximately 18 months), and New Drug Approval can exceed valuations above $1 Billion. The Company has numerous, improved high-impact cancer drugs advancing with proper support.NDA is required for comprehensive Confidential Information Memorandum crafted by ProNova Partners.

Cash Flow Not Disclosed
Revenue Not Disclosed
$ Owner Financing Available

loading...
TOP â–²
Add Businesses and/or Franchises
To Basket For Free Information

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our cookies information for more details.